Dyslipidemia in patients with chronic kidney disease
Chronic kidney disease (CKD) is associated with high risk for cardiovascular disease (CVD). This association is multifactorial, but CKD is often associated with dyslipidemia, which likely contributes. Patients with CKD have dyslipidemia even at early stages of renal dysfunction and dyslipidemia tend...
Gespeichert in:
| Veröffentlicht in: | Reviews in endocrine & metabolic disorders 2017-03, Vol.18 (1), p.29-40 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 40 |
|---|---|
| container_issue | 1 |
| container_start_page | 29 |
| container_title | Reviews in endocrine & metabolic disorders |
| container_volume | 18 |
| creator | Hager, Matthew R. Narla, Archana D. Tannock, Lisa R. |
| description | Chronic kidney disease (CKD) is associated with high risk for cardiovascular disease (CVD). This association is multifactorial, but CKD is often associated with dyslipidemia, which likely contributes. Patients with CKD have dyslipidemia even at early stages of renal dysfunction and dyslipidemia tends to progress with deterioration of kidney function. The dyslipidemia in CKD is largely due to increased triglyceride levels, decreased HDL-C and varying levels of LDL-C. Current management of CKD may also affect lipid levels. Robust clinical trials demonstrate that statins are safe and efficacious in both lipid lowering and prevention of CVD events in pre-end stage CKD and post-transplant. However, there is no evidence of improved CVD outcomes with statin use in dialysis patients. This review will focus on mechanisms underlying dyslipidemia in CKD and clinical trial evidence for lipid lowering therapy in patients with CKD. |
| doi_str_mv | 10.1007/s11154-016-9402-z |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1891885742</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1891885742</sourcerecordid><originalsourceid>FETCH-LOGICAL-c405t-9722afe9093a1a2969299a18bbcc2f3f3f5e0f47bac2e6ede973f5758d66fcfe3</originalsourceid><addsrcrecordid>eNqNkM9LwzAUx4Mobk7_AC9S8OIlmpc2TXKU-RMGXvQc0vTVZW7tbDpk--vN6BQRBPMOCS-f9w35EHIK7BIYk1cBAERGGeRUZ4zTzR4ZgpAp5TnL9-M5VZpqEGJAjkKYMcYh1-KQDLhi26WHJLtZh7lf-hIX3ia-Tpa281h3Ifnw3TRx07apvUvefFnjOil9QBvwmBxUdh7wZLePyMvd7fP4gU6e7h_H1xPqMiY6qiXntkLNdGrBcp1rrrUFVRTO8SqNJZBVmSys45hjiVrGlhSqzPPKVZiOyEWfu2yb9xWGzix8cDif2xqbVTCgNCglZMb_gQrgWkguInr-C501q7aOH4mUkikoqVmkoKdc24TQYmWWrV_Ydm2Ama1909s30b7Z2jebOHO2S14VCyy_J750R4D3QIhX9Su2P57-M_UTOoWOvg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1887318790</pqid></control><display><type>article</type><title>Dyslipidemia in patients with chronic kidney disease</title><source>MEDLINE</source><source>SpringerLink Journals</source><creator>Hager, Matthew R. ; Narla, Archana D. ; Tannock, Lisa R.</creator><creatorcontrib>Hager, Matthew R. ; Narla, Archana D. ; Tannock, Lisa R.</creatorcontrib><description>Chronic kidney disease (CKD) is associated with high risk for cardiovascular disease (CVD). This association is multifactorial, but CKD is often associated with dyslipidemia, which likely contributes. Patients with CKD have dyslipidemia even at early stages of renal dysfunction and dyslipidemia tends to progress with deterioration of kidney function. The dyslipidemia in CKD is largely due to increased triglyceride levels, decreased HDL-C and varying levels of LDL-C. Current management of CKD may also affect lipid levels. Robust clinical trials demonstrate that statins are safe and efficacious in both lipid lowering and prevention of CVD events in pre-end stage CKD and post-transplant. However, there is no evidence of improved CVD outcomes with statin use in dialysis patients. This review will focus on mechanisms underlying dyslipidemia in CKD and clinical trial evidence for lipid lowering therapy in patients with CKD.</description><identifier>ISSN: 1389-9155</identifier><identifier>EISSN: 1573-2606</identifier><identifier>DOI: 10.1007/s11154-016-9402-z</identifier><identifier>PMID: 28000009</identifier><language>eng</language><publisher>New York: Springer US</publisher><subject>Diabetes ; Dyslipidemias - blood ; Dyslipidemias - drug therapy ; Endocrinology ; Humans ; Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use ; Internal Medicine ; Medicine ; Medicine & Public Health ; Renal Insufficiency, Chronic - blood</subject><ispartof>Reviews in endocrine & metabolic disorders, 2017-03, Vol.18 (1), p.29-40</ispartof><rights>Springer Science+Business Media New York (outside the USA) 2016</rights><rights>Reviews in Endocrine and Metabolic Disorders is a copyright of Springer, 2017.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c405t-9722afe9093a1a2969299a18bbcc2f3f3f5e0f47bac2e6ede973f5758d66fcfe3</citedby><cites>FETCH-LOGICAL-c405t-9722afe9093a1a2969299a18bbcc2f3f3f5e0f47bac2e6ede973f5758d66fcfe3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s11154-016-9402-z$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s11154-016-9402-z$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>313,314,776,780,788,27901,27903,27904,41467,42536,51297</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28000009$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hager, Matthew R.</creatorcontrib><creatorcontrib>Narla, Archana D.</creatorcontrib><creatorcontrib>Tannock, Lisa R.</creatorcontrib><title>Dyslipidemia in patients with chronic kidney disease</title><title>Reviews in endocrine & metabolic disorders</title><addtitle>Rev Endocr Metab Disord</addtitle><addtitle>Rev Endocr Metab Disord</addtitle><description>Chronic kidney disease (CKD) is associated with high risk for cardiovascular disease (CVD). This association is multifactorial, but CKD is often associated with dyslipidemia, which likely contributes. Patients with CKD have dyslipidemia even at early stages of renal dysfunction and dyslipidemia tends to progress with deterioration of kidney function. The dyslipidemia in CKD is largely due to increased triglyceride levels, decreased HDL-C and varying levels of LDL-C. Current management of CKD may also affect lipid levels. Robust clinical trials demonstrate that statins are safe and efficacious in both lipid lowering and prevention of CVD events in pre-end stage CKD and post-transplant. However, there is no evidence of improved CVD outcomes with statin use in dialysis patients. This review will focus on mechanisms underlying dyslipidemia in CKD and clinical trial evidence for lipid lowering therapy in patients with CKD.</description><subject>Diabetes</subject><subject>Dyslipidemias - blood</subject><subject>Dyslipidemias - drug therapy</subject><subject>Endocrinology</subject><subject>Humans</subject><subject>Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use</subject><subject>Internal Medicine</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Renal Insufficiency, Chronic - blood</subject><issn>1389-9155</issn><issn>1573-2606</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNqNkM9LwzAUx4Mobk7_AC9S8OIlmpc2TXKU-RMGXvQc0vTVZW7tbDpk--vN6BQRBPMOCS-f9w35EHIK7BIYk1cBAERGGeRUZ4zTzR4ZgpAp5TnL9-M5VZpqEGJAjkKYMcYh1-KQDLhi26WHJLtZh7lf-hIX3ia-Tpa281h3Ifnw3TRx07apvUvefFnjOil9QBvwmBxUdh7wZLePyMvd7fP4gU6e7h_H1xPqMiY6qiXntkLNdGrBcp1rrrUFVRTO8SqNJZBVmSys45hjiVrGlhSqzPPKVZiOyEWfu2yb9xWGzix8cDif2xqbVTCgNCglZMb_gQrgWkguInr-C501q7aOH4mUkikoqVmkoKdc24TQYmWWrV_Ydm2Ama1909s30b7Z2jebOHO2S14VCyy_J750R4D3QIhX9Su2P57-M_UTOoWOvg</recordid><startdate>20170301</startdate><enddate>20170301</enddate><creator>Hager, Matthew R.</creator><creator>Narla, Archana D.</creator><creator>Tannock, Lisa R.</creator><general>Springer US</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QP</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20170301</creationdate><title>Dyslipidemia in patients with chronic kidney disease</title><author>Hager, Matthew R. ; Narla, Archana D. ; Tannock, Lisa R.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c405t-9722afe9093a1a2969299a18bbcc2f3f3f5e0f47bac2e6ede973f5758d66fcfe3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Diabetes</topic><topic>Dyslipidemias - blood</topic><topic>Dyslipidemias - drug therapy</topic><topic>Endocrinology</topic><topic>Humans</topic><topic>Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use</topic><topic>Internal Medicine</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Renal Insufficiency, Chronic - blood</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hager, Matthew R.</creatorcontrib><creatorcontrib>Narla, Archana D.</creatorcontrib><creatorcontrib>Tannock, Lisa R.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Reviews in endocrine & metabolic disorders</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hager, Matthew R.</au><au>Narla, Archana D.</au><au>Tannock, Lisa R.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Dyslipidemia in patients with chronic kidney disease</atitle><jtitle>Reviews in endocrine & metabolic disorders</jtitle><stitle>Rev Endocr Metab Disord</stitle><addtitle>Rev Endocr Metab Disord</addtitle><date>2017-03-01</date><risdate>2017</risdate><volume>18</volume><issue>1</issue><spage>29</spage><epage>40</epage><pages>29-40</pages><issn>1389-9155</issn><eissn>1573-2606</eissn><abstract>Chronic kidney disease (CKD) is associated with high risk for cardiovascular disease (CVD). This association is multifactorial, but CKD is often associated with dyslipidemia, which likely contributes. Patients with CKD have dyslipidemia even at early stages of renal dysfunction and dyslipidemia tends to progress with deterioration of kidney function. The dyslipidemia in CKD is largely due to increased triglyceride levels, decreased HDL-C and varying levels of LDL-C. Current management of CKD may also affect lipid levels. Robust clinical trials demonstrate that statins are safe and efficacious in both lipid lowering and prevention of CVD events in pre-end stage CKD and post-transplant. However, there is no evidence of improved CVD outcomes with statin use in dialysis patients. This review will focus on mechanisms underlying dyslipidemia in CKD and clinical trial evidence for lipid lowering therapy in patients with CKD.</abstract><cop>New York</cop><pub>Springer US</pub><pmid>28000009</pmid><doi>10.1007/s11154-016-9402-z</doi><tpages>12</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1389-9155 |
| ispartof | Reviews in endocrine & metabolic disorders, 2017-03, Vol.18 (1), p.29-40 |
| issn | 1389-9155 1573-2606 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1891885742 |
| source | MEDLINE; SpringerLink Journals |
| subjects | Diabetes Dyslipidemias - blood Dyslipidemias - drug therapy Endocrinology Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use Internal Medicine Medicine Medicine & Public Health Renal Insufficiency, Chronic - blood |
| title | Dyslipidemia in patients with chronic kidney disease |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-25T13%3A00%3A25IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Dyslipidemia%20in%20patients%20with%20chronic%20kidney%20disease&rft.jtitle=Reviews%20in%20endocrine%20&%20metabolic%20disorders&rft.au=Hager,%20Matthew%20R.&rft.date=2017-03-01&rft.volume=18&rft.issue=1&rft.spage=29&rft.epage=40&rft.pages=29-40&rft.issn=1389-9155&rft.eissn=1573-2606&rft_id=info:doi/10.1007/s11154-016-9402-z&rft_dat=%3Cproquest_cross%3E1891885742%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1887318790&rft_id=info:pmid/28000009&rfr_iscdi=true |